Vir Biotechnology, Inc. VIR Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s change in accrued liabilities?
- Vir Biotechnology, Inc. (VIR) reported change in accrued liabilities of -$17.22M in Q1 2026.
- How has Vir Biotechnology, Inc.'s change in accrued liabilities changed year-over-year?
- Vir Biotechnology, Inc.'s change in accrued liabilities decreased by 195.6% year-over-year, from $18.01M to -$17.22M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.